A new study has tested the hypothesis that patients with serum antibodies against recombinant myelin oligodendrocyte glycoprotein (MOG) and purified myelin basic protein (MBP) are at an increased ...

Tocilizumab and rituximab reduce relapse rates and disability progression in NMOSD, with tocilizumab provides extra benefits in MOGAD.

(Neuron) Sex and ethnicity predicted a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD); treatment shortly after onset lowers the risk of the second event.

(Alzheimer's and Dementia) Early treatment of a first acute myelin oligodendrocyte glycoprotein antibody-associated disease ...